Highlights
- 1Thyroid : official journal of the American Thyroid Association · 2020
- 2NPJ precision oncology · 2026
Publications
Funding
Active
8 grants- Co-IR01CA301637-01The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancerNational Cancer Institute · 2025–2030
- Co-IR01CA297829-01Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancerNational Cancer Institute · 2025–2030
- Co-IR01CA287724-01A1Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancerNational Cancer Institute · 2024–2029
- PISA 252921-01Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari PopulationWeill Cornell Medical College/Qatar · 2025–2027Contract
- Co-IW81XWH-22-1-0375Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer.U.S. Department of Defense · 2022–2027
- Co-IR01CA296867-01A1Elucidating the Role of the Tumor Suppressor KEAP1 in Antitumor ImmunityNational Cancer Institute · 2025–2027
- Co-IHHSN261201500003IPersonalized in vitro models to advance precision health equityNational Cancer Institute · 2024–2027 · via Leidos Biomedical Research
- Co-IR01CA248747-01A1Pre-malignant mutation landscape and risk factors for progression to hematologic cancersNational Cancer Institute · 2021–2027
Completed grants (14)
- Co-IELC 202676-03Research collaboration agreement w/ Eli Lilly and CompanyEli Lilly and Company · 2019–2025BioPharma Alliance
- Co-IR01CA233650-05Collaborative genomic alterations and transcriptional control in prostate cancerNational Cancer Institute · 2019–2025
- Co-INYG 204878-01Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYCNew York Genome Center Inc. · 2020–2024
- Co-IR01CA221152-01A1G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate TumorigenesisNational Cancer Institute · 2018–2023
- Co-IP50CA211024-05Weill Cornell Medicine (WCM) SPORE in Prostate CancerNational Cancer Institute · 2017–2023
- KPR01DK078121-11Improving the Diagnosis of Congenital Genitourinary Birth DefectsNational Institute of Diabetes and Digestive and Kidney Diseases · 2018–2023
- KPHHSN26100008Personalized in vitro models to advance precision medicineNational Cancer Institute · 2019–2023 · via Leidos Biomedical Research
- Co-IR01CA259396-01The DARC side of Breast Cancer Disparities - African Ancestry and Cancer- Related Immune ResponseNational Cancer Institute · 2021–2023
- KPPCF 19YOUN15The impacts of RNA-based classifiers on prostate cancer prognosisProstate Cancer Foundation · 2019–2021
- Co-IW81XWH-17-1-0653Temporal Evolution of N-Myc Signaling and Early Targeting of the Neuroendocrine Phenotype in Prostate CancerU.S. Department of Defense · 2017–2020
- Co-IACT 15050798-02Impact of Therapy on Modulation of Neuroendocrine-Associated Gene Expression in Patients With High Risk, Localized Prostate Cancer Treated With Neoadjuvant Docetaxel and Androgen Deprivation TherapyAlliance for Clinical Trials in Oncology · 2015–2018
- Sub-PIW81XWH-16-1-0397Large Oncosomes: A Novel Liquid Biopsy for Genetic Profiling in Patients with Castration Resistant Prostate CancerU.S. Department of Defense · 2016–2018 · via Cedars-Sinai Medical Center
- Co-IU10CA180821-04Molecular Mechanics of Response to Combination Therapy in Early Lethal PCANational Cancer Institute · 2016–2018 · via The Brigham & Women's Hospital INC
- KPR01CA152057-03 EWComprehensive Prostate Cancer Characterization by Genomic and Transcriptomic ProfilingNational Cancer Institute · 2011–2015
News mentions
- Tumor Organoid Tech Advances Toward a Sci-Fi FutureJuly 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
- Prostate Cancer Foundation Awards Grants to Weill Cornell Medicine InvestigatorsMarch 26, 2026
Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation.
- Students Design AI-Powered Health Solutions at Cornell Health HackathonMarch 19, 2026
More than 100 students from across Cornell campuses and 17 other universities gathered in New York City March 6–8 for the Cornell Health AI Hackathon.
- It’s an Absolute Miracle: Battling a Deadly Blood Cancer, a New Jersey Woman Gets a Second Chance — Thanks to Precision MedicineSeptember 7, 2021
Battling a deadly blood cancer, a New Jersey woman gets a second chance — thanks to precision medicine
- Molecular Characterization Can Help Predict How Prostate Cancer Will BehaveMay 17, 2021
Molecular characteristics detected in prostate cancers can provide clues that help predict how the disease will progress, according to new research from investigators at Weill Cornell Medicine and NewYork-Presbyterian.
Show 2 more mentions
- Germline Whole-Exome Sequencing Reveals Potential New Treatment Opportunities in Bladder CancersDecember 8, 2020
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
- Study Reveals Molecular Landscape of Enlarged Prostates, Suggests Treatment StrategyApril 24, 2020
Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
External relationships
Other
Fondazione Heal Italia